1. A pharmaceutical composition comprising a beta agonist selected from indacaterol and formoterol in combination with a corticosteroid selected from fluticasone and cyclesonide, and optionally one or more pharmaceutically acceptable carriers. The pharmaceutical composition of claim 1, wherein the beta agonist is formoterol. The pharmaceutical composition according to claim 1 or 2, wherein formoterol is present in an amount of from 0.5 to 40 μg. The pharmaceutical composition of claim 1, wherein the corticosteroid is fluticasone. The pharmaceutical composition according to claim 1 or 4, wherein fluticasone is present in an amount of from 0.5 to 800 mcg. The pharmaceutical composition according to claim 1 or 4, wherein the fluticasone is present in the form of a fluticasone ester. The pharmaceutical composition of claim 1, wherein the beta agonist is indacaterol. The pharmaceutical composition according to claim 1 or 7, wherein indacaterol is present in an amount of from 20 to 1200 μg. The pharmaceutical composition of claim 1, wherein the corticosteroid is cyclesonide. The pharmaceutical composition according to claim 1 or 9, wherein the cyclizonide is present in an amount of from 20 to 800 mcg. The pharmaceutical composition of claim 1, wherein the fluticasone is present in the form of a fluticasone furoate. The pharmaceutical composition of claim 1, wherein the indacaterol is present in the form of indacaterol maleate. The pharmaceutical composition of claim 1, comprising indacaterol and fluticasone furoate. The pharmaceutical composition according to claim 1, comprising formoterol and fluticasone furoate. The pharmaceutical composition according to claim 1, comprising indacaterol and cyclesonide. A pharmaceutical composition comprising a beta agonist selected from indacaterol and formoterol in combination with a corticosteroid and one or more a�1. Фармацевтическая композиция, содержащая бета-агонист, выбранный из индакатерола и формотерола в сочетании с кортикост
